Finally, generalizing across kM4 and kM5 parameter space shows that when treatment efficacies are sufficiently strong (e.g. 80% efficacies) dual treatment with CXCR4 inhibitors does not accelerate immunodeficiency relative to untreated individuals (Figure 3C). This evidence concerns the gene CXCR4 and immunodeficiency disease.